Wegovy can cut the risk of heart attack and stroke
LAST UPDATED: Aug 30, 2023
4 MIN READ
HERE'S WHAT WE'LL COVER
A long-term clinical trial found that the weight loss medication Wegovy may reduce the risk of cardiovascular events, such as heart attack and stroke, by as much as 20%, according to the drug’s manufacturer, Novo Nordisk.
These findings could mean big things for people who take Wegovy, including a reduced cardiovascular risk and potentially even cost-savings — since some insurers are more likely to cover heart medications than weight loss drugs.
Get access to GLP-1 medication (if prescribed) and 1:1 support to meet your weight goals
What is Wegovy?
Wegovy is one brand name of the medication semaglutide and is FDA-approved to treat obesity when used in combination with a reduced-calorie diet and increased physical activity. It may be prescribed to people with obesity (defined as a body mass index, or BMI, of 30 or higher) or people who have a BMI of 27 or higher and a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes.
Wegovy is part of a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. These medications work by mimicking GLP-1, a gut hormone involved in insulin secretion and appetite control. GLP-1 medications like Wegovy slow gastric emptying (or how quickly food travels along your digestive system), so food takes longer to leave your stomach, making you feel full sooner and for longer. They also send signals to the brain that you’re full, and may even influence which foods you find palatable, further reducing your appetite and leading to weight loss.
In clinical trials, people taking Wegovy lost nearly 15% of their body weight, on average, within a year and a half of starting treatment. On its own, this amount of weight loss can improve a range of chronic conditions and several cardiovascular risk factors, including lowering elevated blood pressure and reducing lipid levels. However, Wegovy had not been shown to directly reduce major cardiovascular events (like heart attack and stroke) until these most recent findings from the SELECT trial.
Wegovy contains the same active ingredient, semaglutide, as Ozempic, a diabetes medication that may be prescribed off-label for weight loss. Ozempic is intended for people with type 2 diabetes. It treats both high blood sugar, and, in people who have both type 2 diabetes and established heart disease, reduces the risk of experiencing a major cardiovascular event. Clinical trials have found that Ozempic reduces cardiovascular risk by as much as 26% among people with type 2 diabetes and heart disease.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
New trial finds Wegovy reduces risk of heart attack and stroke by 20%
In August 2023, Novo Nordisk announced that Wegovy reduced the risk of a major cardiovascular event — including heart attack, stroke, or death — by 20%. The clinical trial involved over 17,600 adults aged 45 and up with overweight or obesity and established heart disease, but no diabetes. The findings are a big deal because they’re the first to confirm that Wegovy can do more than help with weight loss.
These results are in line with other research that has found cardiovascular benefits from similar medications, including other GLP-1 receptor agonists like Ozempic and Saxenda, as well as stimulants like phentermine. These benefits may include reductions in blood pressure, overall cholesterol, triglycerides, and LDL (or “bad”) cholesterol.
We still don’t know all the details of the clinical trial, including the risk breakdown by individual, amount of weight lost, or the prevalence of side effects — just that Wegovy was safe and well-tolerated, which we know from previous clinical trials. The findings have yet to be published in a peer-reviewed journal or reviewed by anyone outside of the company, for that matter. Novo Nordisk plans to release the full findings later this year.
Based on the results of this clinical trial, Novo Nordisk plans to ask the U.S. Food and Drug Administration to add cardiovascular benefits to the prescription label for Wegovy later this year.
Lower cardiovascular risk and other health benefits of weight loss
“We don't know the mechanism yet by which [Wegovy] reduces cardiovascular risk,” shared Dr. Beverly Tchang, an endocrinologist who treats patients with obesity, and an advisor to Ro. “It might be driven by weight loss or by more direct mechanisms like improvements in blood vessel function.”
Heart disease is the leading cause of death for men and women globally, while the number of people with overweight or obesity has nearly tripled in the last fifty years. Risk factors for heart disease include obesity, high blood pressure, high cholesterol, diabetes, and smoking. Obesity increases the risk of high blood pressure, high cholesterol, type 2 diabetes, stroke, some cancers, and the chance of dying from heart attack or stroke — which are the leading causes of death among people with obesity.
Weight loss can help with both heart disease and obesity, as well as a range of conditions that include polycystic ovarian syndrome (PCOS), infertility (by restoring ovulation through weight loss in people with PCOS), type 2 diabetes, sleep apnea, and non-alcoholic fatty liver disease. “Weight loss of just 5% has been shown to improve cholesterol, blood pressure, and blood sugar,” shared Dr. Tchang. “Higher amounts of weight loss can even fully treat diabetes or fatty liver disease.”
Fad diets stop here
If appropriate, get effective weight loss treatment prescribed for your body.
How might this news affect insurance coverage for Wegovy?
Despite the growing, overwhelming evidence of obesity as a disease (and the American Medical Association officially recognizing it as such a decade ago), there is still a misconception of weight loss medications as “vanity drugs.”
As a result, insurance companies don’t always consider these medications medically necessary, and won’t provide coverage. In particular, Medicare Part D does not provide coverage for weight loss medications, but it’s also possible that private insurance plans may not cover drugs like Wegovy.
“We hope to see better coverage for Wegovy since insurance companies have historically taken heart medications more seriously, though in reality, we're finding Wegovy to be an all-around metabolism medication with multiple benefits,” shared Dr. Tchang.
For now, we’ll have to wait and see. Once the full findings from the clinical trial are published, we’ll know more about what change — if any — these heart benefits may have on insurance coverage for Wegovy. In the meantime, people can save on Wegovy by price-shopping at different pharmacies, and taking advantage of Patient Assistance Programs and the Wegovy savings card if they’re eligible.
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
American Medical Association. (2013). *Recognition of Obesity as a Disease H-440.842. * Retrieved Aug. 29, 2023 from https://policysearch.ama-assn.org/policyfinder/detail/obesity?uri=%2FAMADoc%2FHOD.xml-0-3858.xml
Bramante, C. T., Raatz, S., Bomberg, E. M., et al. (2020). Cardiovascular Risks and Benefits of Medications Used for Weight Loss. Frontiers in Endocrinology, 10. doi:10.3389/fendo.2019.00883. Retrieved from https://www.frontiersin.org/articles/10.3389/fendo.2019.00883/full
Farhana, A., & Rehman, A. (2023). Metabolic Consequences of Weight Reduction. StatPearls. Retrieved Aug. 28, 2023 from https://www.ncbi.nlm.nih.gov/books/NBK572145/
Flora, G. D. & Nayak, M. K. (2019). A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. Current Pharmaceutical Design, 25(38), 4063–4084. doi:10.2174/1381612825666190925163827. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31553287/
Husain, M., Bain, S. C., Holst, et al. (2020). Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovascular Diabetology, 19(1). doi:10.1186/s12933-020-01106-4. Retrieved from https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01106-4
Kosiborod, M. N., Bhatta, M., Davies, M., et al. (2023). Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obesity & Metabolism, 25(2), 468–478. doi:10.1111/dom.14890. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092593/
Lin, X. & Li, H. (2021). Obesity: Epidemiology, Pathophysiology, and Therapeutics. *Frontiers in Endocrinology, 12, * 706978. doi:10.3389/fendo.2021.706978. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450866/
Lingvay, I., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.), 31(1), 111–122. Retrieved from https://pubmed.ncbi.nlm.nih.gov/36502289/
Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. doi:10.1056/nejmoa1607141. Retrieved from https://www.nejm.org/doi/full/10.1056/nejmoa1607141
Novo Nordisk-a. (2023). Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [Press release]. Retrieved Aug. 29, 2023 from https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166301#
Novo Nordisk-b. (2023). Wegovy® (semaglutide) injection 2.4 mg List Price & Insurance Coverage Explained | NovoCare®. Retrieved Aug. 29, 2023 from https://www.novocare.com/obesity/products/wegovy/let-us-help/explaining-list-price.html
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine: The Official Publication of the American Federation for Clinical Research, 70(1), 5–13. doi:10.1136/jim-2021-001952. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/
U.S. Food and Drug Administration (FDA-a). (2022). Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use. Retrieved Aug. 28, 2023 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s005lbl.pdf
U.S. Food and Drug Administration (FDA-b). (2022). Highlights of Prescribing Information: Ozempic (semaglutide) injection, for subcutaneous use. Retrieved Aug. 28, 2023 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637Orig1s009lbl.pdf
Vafiadis, D. (2021). Obesity Treatment and Medicare: A Guide to Understanding Coverage. National Council on Aging. Retrieved from https://www.ncoa.org/article/obesity-treatment-and-medicare-a-guide-to-understanding-coverage
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. doi:10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2032183